Development of Human Laboratory Study Model of Cocaine Relapse Prevention. - 1

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2004 by National Institute on Drug Abuse (NIDA).
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00040066
First received: June 18, 2002
Last updated: October 23, 2007
Last verified: September 2004
  Purpose

The purpose of this study is to assess the development of human laboratory study model of cocaine relapse prevention.


Condition Intervention Phase
Cocaine-Related Disorders
Procedure: Cocaine (IV)
Phase 1

Study Type: Interventional
Study Design: Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Development of Human Laboratory Study Model of Cocaine Relapse Prevention

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Cocaine craving
  • Cocaine related high

Estimated Enrollment: 32
Study Start Date: May 2002
Estimated Study Completion Date: August 2003
Detailed Description:

The primary objective of this study will be to develop experimental procedures and parameters demonstrating arousal and craving responses to cocaine-related environmental cues as a model for future testing of the relapse prevention medication treatment of cocaine addiction.

  Eligibility

Ages Eligible for Study:   18 Years to 55 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cocaine dependent, non treatment seeking individuals

Exclusion Criteria:

Please contact site directly for details.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00040066

Locations
United States, California
UCLA Integrated Substance Abuse Program
Los Angeles, California, United States, 90024
United States, Texas
University of Texas Health Science Center
San Antonio, Texas, United States, 78284
Sponsors and Collaborators
Investigators
Principal Investigator: John Roache, Ph.D. National Institute on Drug Abuse (NIDA)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00040066     History of Changes
Other Study ID Numbers: NIDA-CTO-0013-1
Study First Received: June 18, 2002
Last Updated: October 23, 2007
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Cocaine
Vasoconstrictor Agents
Cardiovascular Agents
Therapeutic Uses
Pharmacologic Actions
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Anesthetics, Local
Anesthetics
Central Nervous System Depressants
Sensory System Agents
Peripheral Nervous System Agents
Central Nervous System Agents

ClinicalTrials.gov processed this record on April 15, 2014